Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03342638 · ClinicalTrials.gov registry record · Phase 3
Maximizing Outcome of Multiple Sclerosis Transplantation
A Phase 3 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 66
- Enrollment target
NCT03342638 is a Phase 3 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 66 participants.
The verdict
NCT03342638, a Phase 3 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 66 participants
- Enrollment target
Study Summary
Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).
Interventions
- DRUG Cyclophosphamide
- DRUG Mesna
- DRUG G-CSF
- DRUG Methylprednisolone
- DRUG rATG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-11-08 |
| Est. Completion | 2019-10-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03342638
The ClinicalTrials.gov registry entry for NCT03342638 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03342638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03342638 about?
NCT03342638 is a clinical study titled "Maximizing Outcome of Multiple Sclerosis Transplantation". Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).
What is the current status of trial NCT03342638?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 66 participants. The study started on 2017-11-08. Estimated completion is 2019-10-09.
What interventions are being tested in trial NCT03342638?
The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), G-CSF (DRUG), Methylprednisolone (DRUG), rATG (DRUG).
Who is sponsoring clinical trial NCT03342638?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.